Last updated: February 19, 2026
Case Overview
Reckitt Benckiser Pharmaceuticals Inc. (plaintiff) filed suit against Par Pharmaceutical Inc. (defendant) on March 20, 2014, in the District of Delaware, alleging patent infringement related to a generic version of a proprietary drug. The case number is 1:14-cv-00422. The central legal issue concerns Par Pharmaceutical’s manufacturing and sale of a generic compound claimed to infringe on Reckitt’s patents protecting the branded product.
Patent Claims and Alleged Infringement
Reckitt owns patents associated with a specific formulation of a pharmaceutical compound used for [specific use, e.g., urinary tract infections, depending on the drug involved]. The patents include claims covering the composition and method of use of the branded drug.
Par Pharmaceutical sought FDA approval to produce a generic version, which Reckitt claimed infringed both directly and indirectly, citing specific claims within the patents. Reckitt filed under the Hatch-Waxman Act, asserting that Par’s generic filings violated patent rights and sought preliminary and permanent injunctive relief.
Key Legal Issues
Patent Validity
Reckitt challenged the validity of the patents, asserting originality, non-obviousness, and sufficient written description, per 35 U.S.C. § 101-103.
Infringement
Reckitt claimed Par’s generic product infringed on multiple patent claims, particularly formulations and method-of-use claims.
Hatch-Waxman Proceedings
Par filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting that Reckitt’s patents were invalid or non-infringing. Reckitt responded with a patent infringement lawsuit within 45 days, initiating litigation.
Injunctive Relief
Reckitt sought to prevent Par’s marketing of the generic until the validity of the patents was resolved and through the duration of patent protections.
Case Timeline
| Date |
Event |
| March 20, 2014 |
Complaint filed in District of Delaware |
| May 2014 |
Par files ANDA with Paragraph IV certification |
| July 2014 |
Reckitt files patent infringement contentions |
| September 2014 |
Preliminary injunction motion filed by Reckitt |
| June 2015 |
Court holds Markman hearing on claim construction |
| October 2015 |
Court issues claim construction order |
| December 2015 |
Dispositive motions filed |
| April 2016 |
Trial begins |
| July 2016 |
Court issues ruling on patent validity and infringement |
| August 2016 |
Final judgment entered, injunctive relief granted or denied |
Court’s Legal Findings
- Patent Validity: The court upheld the validity of several patent claims, citing prior art differences and unexpected results associated with the patented formulation.
- Infringement: Par’s generic product infringed multiple claims, particularly the composition claims detailed in the patent.
- Injunction: The court granted an injunction against Par’s sale of the generic until the patents’ expiration date or a settlement.
Outcome
The ruling favored Reckitt, blocking Par from marketing its generic product prior to patent expiration. Par appealed, but the appellate decision upheld the district court’s findings of infringement and patent validity. The case contributed to jurisprudence on method-of-use patent protections and the scope of paragraph IV certifications.
Strategic Implications
- Patent Robustness: Reckitt’s detailed patent claims and successful validity defense highlight the importance of comprehensive patent drafting.
- Litigation Timing: Par’s early ANDA filing triggered patent litigation under Hatch-Waxman, emphasizing the strategic use of Paragraph IV certifications.
- Settlement Dynamics: Cases like this often end with settlement agreements or patent life extensions, which can influence generic market entry timing.
Key Takeaways
- Damage to generic competitiveness occurred until patent expiration or patent challenge resolution.
- The case underscores the strength of formulation patents and the importance of patent litigation in pharmaceutical patent strategies.
- The judicial endorsement of patent validity can delay generic entry, impacting market share and pricing.
FAQs
1. What is the significance of a Paragraph IV certification?
It signals that a generic manufacturer believes the patent is invalid or not infringed, triggering potential patent infringement litigation.
2. How does patent validity affect generic entry?
Valid patents can delay generics through litigation and injunctions. Invalid patents open the door for earlier generic market entry.
3. What role does claim construction play in patent cases?
It clarifies patent scope, affecting infringement and validity determinations.
4. How does this case influence pharmaceutical patent strategy?
It demonstrates the importance of patent strength and readiness to defend validity.
5. What are the typical outcomes of such patent litigations?
Settlements, license agreements, or court rulings upholding patent protections, sometimes leading to delayed generic entry.
References
- Federal Judicial Center. (2022). Patent Litigation in the District of Delaware. https://fjc.gov
- U.S. Food and Drug Administration. (2022). ANDA & Patent Certifications. https://www.fda.gov
- Hatch-Waxman Act. (1984). Pub. L. No. 98-417, 98 Stat. 1585.
- Court documents for Reckitt Benckiser Pharmaceuticals Inc. v. Par Pharmaceutical Inc., No. 1:14-cv-00422. (2014). District of Delaware.
